What is Dentatorubral Pallidoluysian Atrophy?

Dentatorubral-pallidoluysian atrophy (DRPLA) is a genetic condition that worsens over time, leading to a variety of symptoms including muscle spasms, unstable movement, involuntary writhing motions, cognitive issues like dementia, and mental health problems. Occasionally, it can also cause degeneration of the inner layer of the cornea, head tremors, or damage to the optic nerve. The symptoms can differ based on the age at which the disorder starts. DRPLA was first identified in 1946 and was named in 1958.

What Causes Dentatorubral Pallidoluysian Atrophy?

Dentatorubral-pallidoluysian atrophy is a result of a repeat expansion of three specific molecules (cytosine, adenine, and guanine) in a particular gene, known as atrophin-1. This gene, located on a specific part of chromosome 12, helps control the activity of other genes and is active in the brain and other organs.

Normally, these three molecules repeat between 6-35 times. However, in people with this condition, they can repeat from 48 to 93 times. The more times these molecules repeat, the more severe the condition generally is. However, there are some rare exceptions where patients have a high number of repeats but show no symptoms.

The severity of the condition really starts to show when there are more than 48 repeats, which typically produce the common symptoms of the disease. Those with 35 to 47 repeats tend to have milder symptoms. Interestingly, Japanese patients tend to have a higher baseline number of repeats compared to people of European descent, yet the condition manifests similarly in both Asian and non-Asian populations.

Risk Factors and Frequency for Dentatorubral Pallidoluysian Atrophy

Dentatorubral-pallidoluysian atrophy, often shorted to DRPLA, usually begins around 31 years of age. It is primarily seen in Asian populations, notably in Japan where the rate is between 2 to 7 people per million. The rate among all Japanese people is thought to be between 0.2 to 0.4 in 100,000 people. Although it was first found in Asian populations, it’s now seen in other groups around the world thanks to improved genetic testing.

When we look at all the global cases of DRPLA among a related group of conditions known as spinocerebellar ataxia (SCA), we see the highest rates again in Japan (7 to 20%). There are lower rates are in other Asian populations like Singapore and Korea (6% and 3% respectively), Portuguese families (2 to 4%), people of European descent (0.25 to 1%), and Latin-American families (0.14 to 3.1%). It affects both men and women the same.

The disease manifests differently in different age groups. For instance, those who develop the disease as juveniles (younger than 20 years of age) and have a form called progressive myoclonic epilepsy (PME), usually experience seizures and some type of issue with their neurological development. Genetically, this group tends to have longer CAG repeat lengths (more than 65), and the disease progression typically involves generalized seizures and muscle spasms with progressively worsening intellectual disability.

Adults who develop the disease (older than 20 years of age), on the other hand, show symptoms that include a lack of physical coordination, abnormal involuntary movement, cognitive impairment, dementia, and disruptions in mental health. This group tends to have shorter CAG repeat lengths (fewer than 65), and seizures are an uncommon symptom.

Signs and Symptoms of Dentatorubral Pallidoluysian Atrophy

Dentatorubral-pallidoluysian atrophy, or DRPLA, is a complex condition to diagnose because its symptoms can vary greatly and may resemble other disorders like spinocerebellar ataxias. The symptoms and brain scan results can change based on when the condition begins to show. For example, if DRPLA begins after the age of 20, it may show up as uncoordinated movements, involuntary muscle movements, psychiatric symptoms like delusions, cognitive decline, and sometimes head tremors and vision issues.

However, if DRPLA begins before someone turns 20, the symptoms can be quite different:

  • Sudden, involuntary muscle contractions (myoclonus)
  • Different forms of seizures
  • Changes in behavior
  • Intelligence decline and a worsening mental state
  • Uncoordinated movements (ataxia)

Examinations may reveal issues with complex cognitive functions, speech, memory, coordination, strength, signs of nerve damage in the brain and spinal cord, and difficulty walking.

Testing for Dentatorubral Pallidoluysian Atrophy

Dentatorubral-pallidoluysian atrophy (DRPLA) is a condition that doesn’t have specific clinical signs for diagnosis. Doctors typically consider the symptoms, the patient’s family history, and their ancestry to decide if specific genetic testing is required. This testing involves a procedure known as a Polymerase Chain Reaction (PCR) that amplifies a specific region of the ATN1 gene.

When the gene has a larger number of repeats, another technique, called a capillary electrophoresis-Southern Blot, is used to confirm the diagnosis. While more comprehensive testing techniques, such as whole-genome sequencing, show promise, they are not yet validated for detecting the specific DNA changes seen in DRPLA.

An Electroencephalogram (EEG) – a test that evaluates electrical activity in the brain – can be useful if seizures are suspected. Typically, seizures in DRPLA start with specific movements and can progress to seizures that involve the entire body.

Brain imaging using Magnetic Resonance Imaging (MRI) may show atrophy – a loss of nerve cells and connections – in specific brain regions. However, these changes are not specific to DRPLA and can be seen in other conditions as well.

There’s also research into the use of blood protein levels as biological markers for DRPLA. Studies have found that albumin levels, in particular, may be inversely related to the size of the DNA repeat in the ATN1 gene.

Advanced sequencing technologies are showing promise, but none have been widely adopted or validated yet for detecting the specific gene changes seen in DRPLA.

Treatment Options for Dentatorubral Pallidoluysian Atrophy

Currently, there is no cure for a rare hereditary brain disorder known as dentatorubral-pallidoluysian atrophy. The treatment mainly focuses on supportive care. Genetic counseling is crucial for patients and their families because this condition is passed down through families, and there are significant ethical issues to consider before revealing the diagnosis.

If a patient shows signs of seizures, a suitable anti-seizure medication can be chosen based on the specific features of their seizures. All anti-seizure medications have proven to be effective, but specific drugs like levetiracetam and perampanel have shown particular promise for juvenile-onset cases. Medications like tetrabenazine, risperidone, and gabapentin help manage movement disorders associated with the condition. Certain drugs like riluzole and amantadine may potentially alleviate symptoms like poor coordination and balance, although they are avoided in patients who are pregnant or plan to become pregnant due to unclear effects on the unborn child.

Psychological and psychiatric assessment can be very useful in identifying significant cognitive impairments and mood disorders and improve the patients’ quality of life. Physical and occupational therapy can also support patients’ ability to carry out everyday tasks. Additionally, tailored educational programs are crucial for children with the disease. An interprofessional team of providers can address all the different health issues linked to the condition and enhance patients’ quality of life. Avoiding general anesthesia during surgical procedures can reduce the chances of unforeseen seizures.

Researchers are currently exploring potential therapeutic strategies such as gene silencing for treatment, which has shown some success in treating similar genetic disorders in animal models. Experimental techniques involving the use of molecules that interfere with the faulty gene’s function are also promising. However, they pose significant challenges such as high costs, time-consuming processes, potential for poor absorption, and risk of allergic reactions.

Diagnosing a disease called dentatorubral-pallidoluysian atrophy can be a bit tricky if there’s no known history of the disease in the family. This condition’s symptoms are sometimes similar to other hereditary or developed disorders that affect coordination and balance. If the diagnosis isn’t clear, a broad set of tests, including genetic studies and metabolic evaluations, can be done to help. Advanced brain imaging and studies of the fluid around the brain and spinal cord along with blood tests may also aid in ruling out other existing conditions.

For adults starting to show signs of this disease, doctors might need to consider other conditions such as Huntington’s disease, spinocerebellar ataxia (a group of disorders that cause problems in movement), certain forms of Parkinson’s disease, damage due to alcohol, disorders caused by toxins or metabolic diseases interfering with balance, and paraneoplastic syndromes (conditions that happen as a reaction to cancer in the body).

In younger patients, it’s also important to rule out other conditions including a variety of epilepsy disorders, Lafora disease (a rare genetic disorder that affects the brain), Unverricht-Lundborg disease (a rare inherited form of epilepsy), infantile neuroaxonal dystrophy (a nerve disorder that usually begins in infancy), neuroferritinopathy (a movement disorder), hexosaminidase A deficiency (a disorder that affects the nerves), neuronal ceroid lipofuscinosis (a group of disorders that affect the brain and nervous system), Gaucher’s disease, and several other rare inherited disorders.

What to expect with Dentatorubral Pallidoluysian Atrophy

Dentatorubral-pallidoluysian atrophy (DRPLA) is a condition where cure is still not available. On average, people with the disorder live up to 49 years. The time span from when the disease starts to when it leads to death is typically around 15 years. The age at which the disease starts, the severity of symptoms, and the overall lifespan are all influenced by a specific genetic factor, known as CAG repeat expansion in the ATN1 gene. When there are more than 48 repeats of this gene, it tends to cause an early onset of severe symptoms, and a shortened lifespan.

Additionally, the more CAG repeats there are, the more severe the physical impairments will be, negatively affecting the person’s quality of life and increasing their disability.

One particular characteristic of DRPLA is known as genetic anticipation. This means that each successive generation is likely to develop the disease earlier in life and experience more severe symptoms. This makes the condition a challenge as it passes down to the next generation.

Possible Complications When Diagnosed with Dentatorubral Pallidoluysian Atrophy

People dealing with dentatorubral-pallidoluysian atrophy may face several complications. Here is a list of some potential issues that can occur:

  • Progressive repetitive seizures
  • Status epilepticus
  • Difficulties in swallowing solids or liquids, which could potentially lead to aspiration pneumonia

Preventing Dentatorubral Pallidoluysian Atrophy

Dentatorubral-pallidoluysian atrophy, or DRPLA, is a serious disease which impacts not only the person with the condition but also their children. Both those suffering from the disease and their children need extensive advice and support. This is because DRPLA is a hereditary disorder, meaning it can be passed down from parent to child. Whether symptoms start early in childhood or later in adulthood can change their severity. It’s a coin flip situation: a parent who has DRPLA has a 50% chance of spreading the disease to their child, regardless of the child’s gender.

DRPLA causes an unusual build-up of proteins in the nervous system, essentially disrupting normal functionalities and leading to brain cell death. Unfortunately, there is no known cure for this condition. Anyone diagnosed with DRPLA generally has a poor outlook. On average, the disease lasts about 15 years, with a life expectancy ranging from 8 to 16 years after the first symptoms appear. Recognizing DRPLA early may help patients understand their condition better, potentially improving their access to helpful services and treatments.

For those impacted by DRPLA, reaching out to healthcare experts for advice is critical. These specialists can be found through advocacy groups, academic medical centers, clinical trials, or by consulting published medical research. If finding a local specialist is a challenge, consider getting in touch with national or international experts. There are also several global organizations that offer support for people with DRPLA. These include the National Ataxia Foundation, Ataxia UK, the European Federation of Hereditary Ataxias, the Epilepsy Foundation, and RareConnect.

Frequently asked questions

Dentatorubral-pallidoluysian atrophy (DRPLA) is a genetic condition that worsens over time, leading to a variety of symptoms including muscle spasms, unstable movement, involuntary writhing motions, cognitive issues like dementia, and mental health problems. Occasionally, it can also cause degeneration of the inner layer of the cornea, head tremors, or damage to the optic nerve.

Dentatorubral Pallidoluysian Atrophy is seen in Asian populations, notably in Japan where the rate is between 2 to 7 people per million.

The signs and symptoms of Dentatorubral Pallidoluysian Atrophy (DRPLA) can vary depending on when the condition begins to show. If DRPLA begins after the age of 20, the following signs and symptoms may be present: - Uncoordinated movements - Involuntary muscle movements - Psychiatric symptoms like delusions - Cognitive decline - Head tremors - Vision issues On the other hand, if DRPLA begins before the age of 20, the signs and symptoms can be different and may include: - Sudden, involuntary muscle contractions (myoclonus) - Different forms of seizures - Changes in behavior - Intelligence decline and a worsening mental state - Uncoordinated movements (ataxia) Examinations may also reveal other issues such as problems with complex cognitive functions, speech, memory, coordination, strength, signs of nerve damage in the brain and spinal cord, and difficulty walking. It is important to note that DRPLA is a complex condition to diagnose and its symptoms can resemble other disorders like spinocerebellar ataxias, making accurate diagnosis challenging.

Dentatorubral-pallidoluysian atrophy is caused by a repeat expansion of three specific molecules (cytosine, adenine, and guanine) in a particular gene known as atrophin-1.

The doctor needs to rule out the following conditions when diagnosing Dentatorubral Pallidoluysian Atrophy: 1. Huntington's disease 2. Spinocerebellar ataxia (a group of disorders that cause problems in movement) 3. Certain forms of Parkinson's disease 4. Damage due to alcohol 5. Disorders caused by toxins or metabolic diseases interfering with balance 6. Paraneoplastic syndromes (conditions that happen as a reaction to cancer in the body) 7. A variety of epilepsy disorders 8. Lafora disease (a rare genetic disorder that affects the brain) 9. Unverricht-Lundborg disease (a rare inherited form of epilepsy) 10. Infantile neuroaxonal dystrophy (a nerve disorder that usually begins in infancy) 11. Neuroferritinopathy (a movement disorder) 12. Hexosaminidase A deficiency (a disorder that affects the nerves) 13. Neuronal ceroid lipofuscinosis (a group of disorders that affect the brain and nervous system) 14. Gaucher's disease 15. Several other rare inherited disorders.

The types of tests needed for Dentatorubral Pallidoluysian Atrophy (DRPLA) include: 1. Genetic testing: This involves a Polymerase Chain Reaction (PCR) procedure to amplify a specific region of the ATN1 gene. If the gene has a larger number of repeats, a capillary electrophoresis-Southern Blot technique is used to confirm the diagnosis. 2. Electroencephalogram (EEG): This test evaluates electrical activity in the brain and can be useful if seizures are suspected. Seizures in DRPLA often start with specific movements and can progress to involve the entire body. 3. Brain imaging using Magnetic Resonance Imaging (MRI): This may show atrophy in specific brain regions, but these changes are not specific to DRPLA and can be seen in other conditions as well. 4. Blood protein levels: Research suggests that blood protein levels, particularly albumin levels, may be inversely related to the size of the DNA repeat in the ATN1 gene and can serve as biological markers for DRPLA. It's important to note that advanced sequencing technologies are still being researched and validated for detecting the specific gene changes seen in DRPLA.

The treatment for Dentatorubral-Pallidoluysian Atrophy mainly focuses on supportive care. This includes genetic counseling for patients and their families, as the condition is hereditary. Anti-seizure medications can be used to manage seizures, with drugs like levetiracetam and perampanel showing promise for juvenile-onset cases. Medications like tetrabenazine, risperidone, and gabapentin help manage movement disorders. Psychological and psychiatric assessment, as well as physical and occupational therapy, can improve patients' quality of life. Tailored educational programs are crucial for children with the disease. Researchers are also exploring potential therapeutic strategies such as gene silencing and experimental techniques involving molecules that interfere with the faulty gene's function.

When treating Dentatorubral Pallidoluysian Atrophy, there can be potential side effects. These include: - Progressive repetitive seizures - Status epilepticus - Difficulties in swallowing solids or liquids, which could potentially lead to aspiration pneumonia

The prognosis for Dentatorubral Pallidoluysian Atrophy (DRPLA) is poor. On average, people with the disorder live up to 49 years, and the time span from when the disease starts to when it leads to death is typically around 15 years. The severity of symptoms and overall lifespan are influenced by a specific genetic factor, known as CAG repeat expansion in the ATN1 gene.

A neurologist.

Join our newsletter

Stay up to date with the latest news and promotions!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

We care about your data in our privacy policy.